Classification of cardiomyopathies: evolution or revolution?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. The role of noncoding genetic variants in cardiomyopathy.Frontiers in cardiovascular medicine · 2023
   Review
2. Carvedilol versus Metoprolol in Patients with Ventricular Tachyarrhythmias.Journal of cardiovascular development and disease · 2022
   Article
3. Echocardiography in the Diagnosis of Cardiomyopathies: Current Status and Future Directions.Reviews in cardiovascular medicine · 2022
   Review
4. Prognostic Value of Cardiac Troponin I in Patients with Ventricular Tachyarrhythmias.Journal of clinical medicine · 2022
   Article
5. Phenotypes of Cardiovascular Diseases: Current Status and Future Perspectives.Phenomics (Cham, Switzerland) · 2021
   Review
6. Aetiological and morphological spectrum of cardiomyopathies in French Guiana: a retrospective study.Open heart · 2020
   Article
7. Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology.Cardiovascular research · 2018
   Review
8. Omega-3 polyunsaturated fatty acids prevent murine dilated cardiomyopathy by reducing oxidative stress and cardiomyocyte apoptosis.Experimental and therapeutic medicine · 2017
   Article
9. The MOGE(S) classification for cardiomyopathies: current status and future outlook.Heart failure reviews · 2017
   Review
10. Cardiomyopathies: MOGE(S): a standardized classification of cardiomyopathies?Nature reviews. Cardiology · 2014
    Article
11. Clinical features, spectrum of causal genetic mutations and outcome of hypertrophic cardiomyopathy in South Africans.Cardiovascular journal of Africa
    Article

Corrections and comments

• Comment on
  The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation.2013

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as